Trianni, Inc.

10 patents currently held · Updated Nov 14, 2026

2 more in force are now held by other companies

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Ending by 2030

Nov 2031

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due Aug 6, 2027
The maintenance fee for Enhanced Immunoglobulin Diversity (US 11,889,821) comes due Aug 6, 2027. Unpaid by Feb 7, 2028, it lapses early.
1 fee due Oct 2, 2027
The maintenance fee for Long germline DH genes and long HCDR3 antibodies (US 11,946,063) comes due Oct 2, 2027. Unpaid by Apr 3, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

1 of the patents on this record was granted since Aug 16, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 10 of 10

Patent	Title	Status	Expires	Confidence
US 10,881,084	Transgenic animals and methods of use In force Term ends Nov 14, 2031 · From the USPTO record	In force	Term ends Nov 14, 2031	From the USPTO record
US 10,662,256	Transgenic mammals and methods of use thereof In force Term ends Mar 28, 2032 · From the USPTO record	In force	Term ends Mar 28, 2032	From the USPTO record
US 12,096,753	Transgenic animals and methods of use In force Term ends May 29, 2033 · From the USPTO record	In force	Term ends May 29, 2033	From the USPTO record
US 12,049,516	Transgenic mammals and methods of use thereof In force Term ends Mar 10, 2034 · From the USPTO record	In force	Term ends Mar 10, 2034	From the USPTO record
US 10,813,346	Enhanced Immunoglobulin Diversity In force Ends no later than Nov 30, 2036 · Medium confidence	In force	Ends no later than Nov 30, 2036	Medium confidence
US 11,889,821	Enhanced Immunoglobulin Diversity In force Term ends Nov 30, 2036 · Medium confidence	In force	Term ends Nov 30, 2036	Medium confidence
US 11,053,288	Enhanced production of immunoglobulins In force Term ends Oct 5, 2037 · From the USPTO record	In force	Term ends Oct 5, 2037	From the USPTO record
US 11,414,478	Single Chain VH and Heavy Chain Antibodies In force Term ends Sep 5, 2038 · High confidence	In force	Term ends Sep 5, 2038	High confidence
US 11,946,063	Long germline DH genes and long HCDR3 antibodies In force Term ends Oct 19, 2038 · From the USPTO record	In force	Term ends Oct 19, 2038	From the USPTO record
US 12,715,906	Single Chain VH and Heavy Chain Antibodies In force Term ends Jul 23, 2041 · High confidence	In force	Term ends Jul 23, 2041	High confidence

Also on record, not counted in the 10: 2 patents in force now held by others. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

5 pending · 9 no status recorded

List them